Dizal Pharmaceutical (DIZAL HK): Synthetic Expert Call Transcript (30 Aug 2026)
The $600 million upfront AstraZeneca deal for sunvozertinib (Zegfrovy) in July 2026 is a massive capital infusion but represents a structural...
98 Views
IPO Databook: Dizal Pharmaceutical (HK) - Aug 2026
Dizal Pharmaceutical is a commercial-stage biopharmaceutical company focused on oncology and hematological diseases, with two commercialized...
98 Views
Primer: Dizal Pharmaceutical (DIZAL HK) - Aug 2026
Dizal has successfully transitioned into a commercial-stage biopharmaceutical company with two approved, first-in-class oncology assets:...
88 Views
Pre-IPO Dizal Pharmaceutical (A/H Listing)-Only Sunvozertinib Is Insufficient for Sustainable Growth
DIZAL's pipeline flaws and heavy reliance on ZEGFROVY raise concerns about long-term sustainability and market prospects,with future performance...
205 Views
Dizal (迪哲医药) A+H: Credible Innovative Products
Dizal aims to raise $100 million with an A+H listing with joint sponsors GS and Huatai. We look at its products, the management and investor...
251 Views